



IHEALTHCARE GROUP HOLDINGS LIMITED

(formerly Unroforce Proprietary Limited)
(Incorporated in the Republic of South Africa)
Registration Number: 2019/155531/06
4AX Share Code: 4AIHGH
ISIN: ZAE400000077

(“iHealthcare Holdings”)

IHEALTHCARE GROUP LIMITED

(formerly Caelum Caeruleum Trading Proprietary Limited)
(Incorporated in the Republic of South Africa)
Registration Number: 2011/009651/06
4AX Share Code: 4AIHG
ISIN: ZAE400000085

(“iHealthcare”)

CHANGES TO THE BOARDS OF DIRECTORS (“Boards”) OF MAJOR SUBSIDIARY COMPANIES

In accordance with paragraph 11.23 of the listing requirements of 4 Africa Exchange Proprietary Limited (“**4AX**”), shareholders of iHealthcare Holdings and iHealthcare (collectively the “**Companies**”) are hereby advised that Mr. Phillip Fouché (“**Mr Fouché**”) will be appointed as the chief executive officer (“**CEO**”) of both IsoClear Proprietary Limited (“**IsoClear**”) and IsoPharm Proprietary Limited (“**IsoPharm**”), being major subsidiaries of the Companies, with immediate effect.

Summary curriculum vitae of Mr. Fouché:

Mr. Fouché holds a B.Com Accounting degree and diploma in Strategic Marketing Management from UNISA. He has over 25 years of executive management experience in roles such as business unit manager, senior vice president and managing director for large national and international concerns.

Mr. Fouché is currently the director of New Business Development for Akacia Medical Proprietary Limited and has worked in business development for companies such as Johnson and Johnson and B. Braun, developing relationships with national private hospital / healthcare groups (Discovery Limited/ Netcare Limited) and international suppliers such as Aesculap in Germany and establishing distributor agreements in African countries such as Botswana, Namibia and Mozambique.

The boards of directors of the Companies welcome the appointment of Mr. Fouché and look forward to his contributions during his tenure as a director of IsoClear and IsoPharm.

Pretoria
16 March 2020

4AX EXTERNAL ISSUER AGENT:
Pallidus Capital Proprietary Limited